Form 4: C4 Therapeutics' Chief Scientific Officer Reports Stock Transactions

Stewart Fisher, Chief Scientific Officer of C4 Therapeutics, reports the vesting of performance restricted stock units and shares withheld for tax obligations.

Summary

• On September 16, 2024, Stewart Fisher, the Chief Scientific Officer of C4 Therapeutics, engaged in transactions involving the company's common stock and performance restricted stock units (PRSUs).
• Fisher acquired 2,250 shares of common stock upon the vesting of PRSUs.
• 661 shares were withheld by C4 Therapeutics to satisfy tax obligations related to the vesting of the PRSUs at a price of $6.36.
• Following these transactions, Fisher directly owns 130,710 shares of C4 Therapeutics common stock and 14,250 performance restricted stock units.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of insider transactions related to compensation.

Positives

• The vesting of performance restricted stock units indicates that certain performance milestones were achieved.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.

Comparison to Industry Standards

• Tracking insider transactions is a common practice in the biotech industry, similar to how investors monitor insider activity at companies like Amgen, Gilead Sciences, and Biogen.
• The vesting of PRSUs is a typical form of executive compensation, aligning executive incentives with company performance, similar to stock option plans used by other biotech firms.

Stakeholder Impact

• The transactions have a minor impact on shareholders as they reflect routine executive compensation and tax obligations.

Key Dates